Rapid Micro Biosystems, Inc.
RPIDHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Rapid Micro Biosystems, Inc. focuses on Medical Devices services and products. Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and. The $104.6M market capitalization puts RPID squarely in micro-cap range for its industry. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Market Cap
$104.6M
Beta
1.47
P/E (TTM)
—
P/E (Fwd)
-2.66
EPS (TTM)
$-1.10
EPS (Fwd)
$-0.79
ROE
-116.7%
ROA
-41.9%
Cash
$23.7M
Total Debt
$23.7M
Free CF
-$19.9M
52W Change
-42.9%
Annual Financials
Cash vs Debt
Where RPID stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, RPID finished 28.13% below its 150-day moving average ($2.88) and 31.68% below its 200-day moving average ($3.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RPID overbought or oversold?
At the July 15, 2026 close, RPID's RSI(14) was 80.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $23.7M in cash and $23.7M in debt, RPID maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$19.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -116.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $17.1M (2022) to $33.6M (2025), reflecting a 96% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RPID.